參考文獻(xiàn)/References:
[1] LIU L,YUAN Y,ZHANG S,et al.Osteoimmunological insights into the pathogenesis of ankylosing spondylitis[J].J Cell Physiol,2021,236(9):6090-6100.
[2] O'RIELLY D D,UDDIN M,RAHMAN P.Ankylosing spondylitis:beyond genome-wide association studies[J].Curr Opin Rheumatol,2016,28(4):337-345.
[3] LIN H,GONG Y Z.Association of HLA-B27 with ankylosing spondylitis and clinical features of the HLA-B27-associated ankylosing spondylitis:a meta-analysis[J].Rheumatol Int,2017,37(8):1267-1280.
[4] AKKOC N,YARKAN H,KENAR G,et al.Ankylosing spondylitis:HLA-B*27-positive versus HLA-B*27-negative disease[J].Curr Rheumatol Rep,2017,19(5):26.
[5] UDDIN M,MAKSYMOWYCH W P,INMAN R,et al.UGT2B17 copy number gain in a large ankylosing spondylitis multiplex family[J].BMC Genet,2013,14:67.
[6] VAN DER LINDEN S,VALKENBURG H A,CATS A.Evalu-ation of diagnostic criteria for ankylosing spondylitis.A proposal for modification of the New York criteria[J].Arthritis Rheum,1984,27(4):361-368
[7] DOUGADOS M,VAN DER LINDEN S,JUHLIN R,et al.The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy[J].Arthritis Rheum,1991,34(10):1218-1227.
[8] 韓仁芳,陳夢(mèng)雅,劉瑞,等.強(qiáng)直性脊柱炎2261例流行特征及功能狀態(tài)現(xiàn)狀分析[J].安徽醫(yī)藥,2017,21(1):73-77.
[9] QIAN Q,XU X,HE H,et al.Clinical patterns and characteristics of ankylosing spondylitis in China[J].Clin Rheumatol,2017,36(7):1561-1568.
[10] 冀肖健,孫鍇,胡拯源,等.強(qiáng)直性脊柱炎患者人類白細(xì)胞抗原-B27分子攜帶狀態(tài)臨床對(duì)比研究:基于脊柱關(guān)節(jié)炎智能移動(dòng)管理系統(tǒng)的真實(shí)世界數(shù)據(jù)[J].中華內(nèi)科雜志,2018,57(3):179-184.
[11] XIONG J,CHEN J,TU J,et al.Association of HLA-B27 status and gender with sacroiliitis in patients with ankylosing spondylitis[J].Pak J Med Sci,2014,30(1):22-27.
[12] REYNOLDS T L,KHAN M A,VAN DER LINDEN S,et al.Differences in HLA-B27 positive and negative patients with ankylosing spondylitis:study of clinical disease activity and concentrations of serum IgA,C reactive protein,and haptoglobin[J].Ann Rheum Dis,1991,50(3):154-157.
[13] HOMS H C,STARK L A.The NF-κB nucleolar stress response pathway[J].Biomedicines,2021,9(9):1082.
[14] HAYDEN M S,GHOSH S.NF-κB,the first quarter-century:remarkable progress and outstanding questions[J].Genes & Development,2012,26(3):203-234.
[15] 任偉凡,胡勁濤,高煬,等.強(qiáng)直性脊柱炎一家系全外顯子組測(cè)序分析[J].中國(guó)骨傷,2020,33(7):672-676.
[16] 張貽強(qiáng),祝星宇,王艷宏,等.天然藥物基于核轉(zhuǎn)錄因子κB信號(hào)通路抗類風(fēng)濕性關(guān)節(jié)炎的機(jī)制研究[J].中國(guó)藥房,2019,30(7):1004-1008.
[17] 趙玉霞,梅紅,彭罕鳴,等.白細(xì)胞介素38通過核因子-κB與信號(hào)轉(zhuǎn)導(dǎo)及轉(zhuǎn)錄激活因子3信號(hào)通路抑制兒童炎癥性腸病的分子機(jī)制[J].中華消化雜志,2019,39(4):237-243.
[18] 王洪武,鄧超,蔡興俊.煙草煙霧暴露對(duì)哮喘小鼠肺組織NF-κB p65表達(dá)的影響[J].中國(guó)熱帶醫(yī)學(xué),2019,19(11):1018-1021.
[19] LI Q,VERMA I M.NF-κB regulation in the immune system[J].Nat Rev Immunol,2002,2(10):725-734.
[20] PASPARAKIS M.Regulation of tissue homeostasis by NF-κB signalling:implications for inflammatory diseases[J].Nat Rev Immunol,2009,9(11):778-788.
[21] MULERO M C,HUXFORD T,GHOSH G.NF-κB,IκB,and IKK:Integral Components of Immune System Signaling[J].Adv Exp Med Biol,2019,1172:207-226.
[22] 韓飛,尤欣,唐福林.核因子κB在類風(fēng)濕關(guān)節(jié)炎滑膜組織中的表達(dá)與意義[J].中華風(fēng)濕病學(xué)雜志,2004,8(3):143-146.
[23] 方利,劉健,朱福兵,等.基于細(xì)胞因子/NF-κB信號(hào)通路探討強(qiáng)直性脊柱炎患者血瘀狀態(tài)形成的機(jī)制[J].中華中醫(yī)藥學(xué)刊,2016,34(12):2913-2917.
[24] SIMMONDS R E,FOXWELL B M.Signalling,inflammation and arthritis:NF-kappaB and its relevance to arthritis and inflammation[J].Rheumatology,2008,47(5):584-590.
[25] MARTIN-MILLAN M,ALMEIDA M,AMBROGINI E,et al.The estrogen receptor-alpha in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone[J].Mol Endocrinol,2010,24(2):323-334.
[26] MCDONALD M M,KIM A S,MULHOLLAND B S,et al.New insights into osteoclast biology[J/OL].JBMR Plus,2021,5(9)[2021-06-09].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441501/.
[27] LIN Z,BEI J X,SHEN M,et al.A genome-wide association study in Han Chinese identifies new susceptibility loci for ankylosing spondylitis[J].Nat Genet,2011,44(1):73-77.
[28] EVANS D M,SPENCER C C,POINTON J J,et al.Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility[J].Nat Genet,2011,43(8):761-767.
[29] LI Z,AKAR S,YARKAN H,et al.Genome-wide associ-ation study in Turkish and Iranian populations identify rare familial Mediterranean fever gene(MEFV)polymorphisms associated with ankylosing spondylitis[J/OL].PLoS Genet,2019,15(4)[2021-06-09].https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6467421/.
[30] JUNG S H,YIM S H,HU H J,et al.Genome-wide copy number variation analysis identifies deletion variants associated with ankylosing spondylitis[J].Arthritis Rheumatol,2014,66(8):2103-2112.
[31] LIU J J,FAN L L,CHEN J L,et al.A novel variant inTBX20(p.D176N)identified by whole-exome sequencing in combination with a congenital heart disease related gene filter is associated with familial atrial septal defect[J].J Zhejiang Univ Sci B,2014,15(9):830-837.
[32] MANOLIO T A,COLLINS F S,COX N J,et al.Finding the missing heritability of complex diseases[J].Nature,2009,461(7265):747-753.
相似文獻(xiàn)/References:
[1]閻曉霞,任之強(qiáng),仝允輝,等.布魯氏菌性脊柱炎3例[J].中醫(yī)正骨,2015,27(06):64.
[2]趙偉光,劉振武,劉利,等.強(qiáng)直性脊柱炎合并右側(cè)股骨頭和股骨頸骨溶解癥1例[J].中醫(yī)正骨,2015,27(01):75.
[3]黃建武,黃建華,黃影.腫瘤壞死因子-α在強(qiáng)直性脊柱炎活動(dòng)期患者中的表達(dá)[J].中醫(yī)正骨,2013,25(11):22.
[4]張董喆,孔超,張建福.針刺夾脊穴結(jié)合督灸治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2014,26(07):58.
[5]吳建國(guó).強(qiáng)直性脊柱炎并發(fā)脊柱骨折的影像學(xué)表現(xiàn)[J].中醫(yī)正骨,2013,25(06):31.
[6]謝國(guó)華,薛峰,楊建平,等.強(qiáng)直性脊柱炎脊柱應(yīng)力性骨折的診斷[J].中醫(yī)正骨,2012,24(12):72.
[7]張萬義,張永紅,王笑青.雙醋瑞因膠囊聯(lián)合柳氮磺胺吡啶腸溶片與右旋布洛芬膠囊治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2012,24(06):26.
ZHANG Wan-yi*,ZHANG Yong-hong,WANG Xiao-qing.*.Study on the curative effects of diacerein capsules combined with sulfasalazine enteric-coated tablets and dextral ibuprofen capsules in the treatment of ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(06):26.
[8]黃建華,黃建武,陳金春,等.早期強(qiáng)直性脊柱炎血管內(nèi)皮生長(zhǎng)因子、C反應(yīng)蛋白
表達(dá)水平的臨床研究[J].中醫(yī)正骨,2012,24(02):9.
HUANG Jian-hua*,HUANG Jian-wu,CHEN Jin-chun,et al.Clinical research on the expression of VEGF、CRP in early ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2012,24(06):9.
[9]王笑青,張永紅,王玉麗,等.常規(guī)藥物口服配合中藥離子導(dǎo)入治療強(qiáng)直性脊柱炎肌腱附著點(diǎn)炎[J].中醫(yī)正骨,2011,23(10):18.
WANG Xiao-qing*,ZHANG Yong-hong,WANG Yu-li,et al.A study on the curative effects of oral conventional drugs combined with traditional Chinese medicine iontophoresis on ankylosing spondylitis tendon enthesitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(06):18.
[10]劉紅軍.單節(jié)段楔形截骨結(jié)合椎弓根A-F系統(tǒng)內(nèi)固定
治療強(qiáng)直性脊柱炎脊柱后凸畸形[J].中醫(yī)正骨,2011,23(09):65.
[11]戴霞華,李寅潔.指導(dǎo)性功能鍛煉在兒童強(qiáng)直性脊柱炎護(hù)理中的應(yīng)用[J].中醫(yī)正骨,2015,27(10):78.
[12]張夢(mèng)雨,鮑鐵周,田江波.督脈隔姜灸聯(lián)合柳氮磺吡啶腸溶片口服及
功能鍛煉治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2015,27(09):44.
[13]赫軍,諸葛天諭,李冬冬,等.中藥內(nèi)服聯(lián)合針刺與埋針法治療幼年強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2016,28(01):41.
[14]赫軍,諸葛天諭,李冬冬,等.四聯(lián)療法治療強(qiáng)直性脊柱炎[J].中醫(yī)正骨,2016,28(06):50.
[15]張遂連,袁星星.自我管理在強(qiáng)直性脊柱炎患者門診護(hù)理中的應(yīng)用[J].中醫(yī)正骨,2017,29(03):79.
[16]李現(xiàn)林,薛華珍,陳星,等.口服通痹舒筋丸治療強(qiáng)直性脊柱炎寒濕痹阻證[J].中醫(yī)正骨,2017,29(05):31.
[17]龔家川.影響強(qiáng)直性脊柱炎患者髖關(guān)節(jié)受累的危險(xiǎn)因素分析[J].中醫(yī)正骨,2017,29(06):25.
GONG Jiachuan.Analysis of risk factors for affection of hip joint in patients with ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(06):25.
[18]黃小龍,全仁夫,胡華輝,等.HLA-B2704基因型強(qiáng)直性脊柱炎患者來源的人誘導(dǎo)多能干細(xì)胞體系的建立[J].中醫(yī)正骨,2017,29(12):11.
HUANG Xiaolong,QUAN Renfu,HU Huahui,et al.Establishment of human-induced pluripotent stem cells system originated from patients with HLA-B2704 genotypic ankylosing spondylitis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2017,29(06):11.
[19]李洛宜,張依山,王笑青,等.系列化視頻在強(qiáng)直性脊柱炎健康教育中的應(yīng)用[J].中醫(yī)正骨,2018,30(03):78.
[20]任偉凡,胡勁濤,全仁夫,等.強(qiáng)直性脊柱炎易感基因的相關(guān)研究進(jìn)展[J].中醫(yī)正骨,2019,31(04):48.